Nchi: Marekani
Lugha: Kiingereza
Chanzo: NLM (National Library of Medicine)
TELMISARTAN (UNII: U5SYW473RQ) (TELMISARTAN - UNII:U5SYW473RQ)
Amneal Pharmaceuticals of New York LLC
TELMISARTAN
TELMISARTAN 20 mg
ORAL
PRESCRIPTION DRUG
Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of
Telmisartan tablets USP, 20 mg, are supplied as white to off-white, round shaped uncoated tablets, debossed with ‘AN’ on one side and ‘291’ on the other side. They are available as follows: Bottles of 30: NDC 53746-291-30 Telmisartan tablets USP, 40 mg, are supplied as white to off-white, modified capsule shaped uncoated tablets, debossed with ‘AN’ on one side and ‘292’ on the other side. They are available as follows: Bottles of 30: NDC 53746-292-30 Telmisartan tablets USP, 80 mg, are supplied as white to off-white, modified capsule shaped uncoated tablets, debossed with ‘AN293’ on one side and plain on the other side. They are available as follows: Bottles of 30: NDC 53746-293-30 Storage Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Tablets should not be removed from bottles until immediately before administration.
Abbreviated New Drug Application
TELMISARTAN- TELMISARTAN TABLET AMNEAL PHARMACEUTICALS OF NEW YORK LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE TELMISARTAN TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TELMISARTAN TABLETS. TELMISARTAN TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1998 WARNING: FETAL TOXICITY _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ WHEN PREGNANCY IS DETECTED, DISCONTINUE TELMISARTAN AS SOON AS POSSIBLE. (5.1, 8.1) DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE INJURY AND DEATH TO THE DEVELOPING FETUS. (5.1, 8.1) INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors. (1.2) DOSAGE AND ADMINISTRATION May be administered with or without food. (2.1) When used for cardiovascular risk reduction, monitoring of blood pressure is recommended, and if appropriate, adjustment of medications that lower blood pressure may be necessary. (2.2) INDICATION STARTING DOSE DOSE RANGE Hypertension (2.1) 40 mg once daily 40 mg to 80 mg once daily Cardiovascular Risk Reduction (2.2) 80 mg once daily 80 mg once daily DOSAGE FORMS AND STRENGTHS Tablets: 20 mg, 40 mg, 80 mg (3) CONTRAINDICATIONS Known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan or any other component of this product. (4) Do not co-administer aliskiren with telmisartan in patients with diabetes. (4) WARNINGS AND PRECAUTIONS Avoid fetal or neonatal exposure. (5.1) Hypotension: Correct any volume or salt depletion before initiating therapy. Observe for signs and symptoms of hypotension. (5.2) Monitor carefully in patients with impaired hepatic (5.4) or renal function. (5.5) Avoid concomitant use of an ACE inhibitor and angiote Soma hati kamili